The Flowr Corporation (TSXV:FLWR) announced today that its subsidiary, The Flowr Group (Okanagan) Inc. (“Flowr” or “Company”), a cultivator of premium cannabis for the Canadian market, has launched direct sales of its FlowrRx brand medical cannabis to customers through its website,  The Company will accept a limited number of customers initially and provide them access to a wide range of cannabis strains.

Along with distribution partnerships that make FlowrRx available through numerous medical clinics, this marks the Company’s entrance into a market that Deloitte has estimated could generate up to C$1.8 billion in sales in 2019.

Flowr’s cultivation team employs exacting protocols throughout the growing and curing process seeking to consistently provide medical clients with their desired medicinal benefits.  Flowr’s products are grown in the world famous Okanagan Valley of British Columbia in facilities that employ proprietary cultivation systems and are engineered to meet pharmaceutical quality production standards.  Flowr then carefully harvests, hand trims and craft cures its products.

“FlowrRx’s premium cannabis is grown to provide our clients with the medicinal benefits they seek  and, most importantly for their care, a consistent experience,” said Dr. Lyle Oberg, Flowr’s Chief Policy and Medical Officer.  “We’re also providing a premium customer service experience with convenient, discreet, online access to obtaining medical documentation and personalized support from our team of client care nurses.”

Program Highlights

Flowr believes all clients who can benefit from the medicinal qualities of cannabis should have easy access to the products they want and need.  Its medical sales program is centered on the patient and built to deliver clients premium products, convenient access and extensive support. This includes:

  • Multiple strains of FlowrRx brand flower ranging from high THC to balanced strains and featuring the Company’s BC Delahaze.  Delahaze is an award winning cultivar known for its powerful, invigorating effects. Flowr’s BC Delahaze is expertly grown in the Company’s indoor facility to emphasize its potency and flavor, including citrus and mango notes, then carefully harvested, hand-trimmed and craft-cured.
  • A convenient, discreet, online medical documentation process.  For clients obtaining medical documents for the first time, Flowr offers online consultation with a healthcare professional from the comfort and convenience of the client’s preferred location.  Clients with medical documentation can contact their current clinic and request a switch to Flowr or split documentation to add Flowr’s premium products to their list of options.
  • Exceptional Client Care.  Flowr will provide personalized support for medical clients through a team of bilingual nurses who can answer questions and help guide clients.
  • A free gift.  New registrants will receive a custom Flowr Kube 2.0 cannabis grinder and High Sierra Pack-N-Go sport backpack with their first order, symbolic of Flowr’s commitment to forging new paths and maintaining a spirit of adventure.

Clients can register or book an online consultation and find FlowrRx product information at

Biography for Dr. Lyle Oberg

Dr. Oberg is a former practicing physician and Member of the Legislative Assembly of Alberta, Canada.  He was elected as the MLA for Bow Valley, AB in 1993. During his 15-year tenure in the Assembly, he held several senior Ministerial portfolios including Minister of Social Services, Minister of Learning, Minister of Infrastructure and Transportation, and Minister of Finance where he oversaw a budget of $38 billion and an asset portfolio of $74 billion.  In 2007, Dr. Oberg started Alberta Investment Management Company (AIMCO) which now has assets in excess of $94 billion. After leaving the Assembly in 2008, Dr. Oberg became CEO for MultiGen Diagnostics, a DNA sequencing company based in San Diego. He is currently: Chairman of the Private Equity Investment Committee for Yorkville Asset Management; Chief Policy and Medical Officer, The Flowr Corporation; Director of Plant Properties REIT; and, Medical Advisor to Strainprint.  He is a graduate of the University of Alberta School of Medicine (1983).

About Flowr

The Flowr Corporation (TSXV: FLWR), through its subsidiaries, is a vertically-integrated Canadian cannabis company focused on the natural science of cannabis.  With head offices in Markham, ON and production in Kelowna, BC, Flowr builds and operates large-scale, GMP designed cultivation facilities utilizing its own patented growing systems.  Flowr’s investment in research and development ensures that its master growers are able to supply patients with consistent, high-quality medicinal cannabis. With a sense of craftsmanship and a spirit of innovation, Flowr is also well positioned with a line of premium quality cannabis products for the upcoming adult-use market.

The Company has agreements with three provinces to provide its premium cannabis for the upcoming adult recreational use market and Flowr has  an exclusive R&D alliance with Hawthorne Gardening, a subsidiary of The Scotts Miracle-Gro Company (NYSE: SMG). Flowr began trading on the TSX Venture Exchange on September 26, 2018 under the symbol FLWR.

For more information, visit   Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; and Instagram: @flowrcanada

On behalf of the Flowr Corporation

Lyle Oberg

Chief Policy & Medical Officer, Director

Forward-Looking Information

Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be   placed on them because the Company can give no assurance that they will prove to be correct. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include information relating to the business plan of Flowr.  Such statements and information reflect the current view of Flowr. Risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: (i) Flowr may require additional financing from time to time in order to continue its operations and financing may not be available when needed or on terms and conditions acceptable to the Resulting Issuer; (ii) new laws or regulations could adversely affect Flowr’s business and results of operations; and (iii) the stock markets have experienced volatility that often has been unrelated to the performance of companies. These fluctuations may adversely affect the price of Flowr’s securities, regardless of its operating performance. There are a number of important factors that could cause Flowr’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: currency fluctuations; limited business history of Flowr; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses, and general market and industry conditions.  The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of Flowr, their securities, or their operating results (as applicable).

Flowr cautions that the foregoing list of material factors is not exhaustive. When relying on Flowr’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Flowr has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Flowr as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Flowr does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

– ends –

Jim Walsh

The Flowr Corporation


Bruce Dunbar

The Flowr Corporation


Alex Dann

The Flowr Corporation


Click here to connect with The Flowr Corporation (TSXV:FLWR) for an Investor Presentation.


Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less